PUBLISHER: The Business Research Company | PRODUCT CODE: 1763081
PUBLISHER: The Business Research Company | PRODUCT CODE: 1763081
The mumps vaccine (MumpsVax) is a live attenuated vaccine that protects against mumps by using the Jeryl Lynn strain of the virus. It is typically administered in two doses and is commonly combined with the MMR (measles, mumps, rubella) vaccine, offering more than 95% protection against mumps. Although standalone production of the mumps vaccine has been discontinued, it continues to play a vital role in public health initiatives to control mumps outbreaks, significantly reducing the incidence of the disease in vaccinated populations.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Mumps vaccine (MumpsVax) is available in several product types, including monovalent, combinational, divalent, trivalent, and others. Monovalent vaccines specifically target mumps, while combinational vaccines provide protection against multiple diseases, such as measles and rubella, in a single shot. The vaccine is used by both pediatric and adult age groups, with distribution through hospital pharmacies, drug stores, and retail pharmacies. It is utilized by a range of end-users, including pediatric clinics, hospitals, non-governmental organizations (NGOs), and others.
The mumps vaccine (mumpsvax) market research report is one of a series of new reports from The Business Research Company that provides mumps vaccine (mumpsvax) market statistics, including mumps vaccine (mumpsvax) industry global market size, regional shares, competitors with a mumps vaccine (mumpsvax) market share, detailed mumps vaccine (mumpsvax) market segments, market trends and opportunities, and any further data you may need to thrive in the mumps vaccine (mumpsvax) industry. This mumps vaccine (mumpsvax) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mumps vaccine (mumpsvax) market size is expected to see strong growth in the next few years. It will grow to $2,902.2 million in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to the rising incidence of vaccine-preventable diseases, growing adult vaccination awareness, rising health consciousness, increasing immunization programs, and increasing international health initiatives. Major trends in the forecast period include personalized vaccination strategies, digital health integration, enhanced surveillance systems, R&D for adult vaccination, and integration of artificial intelligence.
The rising prevalence of infectious diseases is expected to propel the growth of the mumps vaccine (mumpsvax) market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, such as viruses, bacteria, fungi, or parasites, which can be transmitted between individuals or through contaminated environments. Factors such as urbanization, climate change, globalization, and changes in human demographics and behavior contribute to the increased transmission and emergence of pathogens. Mumpsvax is primarily used to prevent mumps, an infectious disease caused by the mumps virus, often included in the MMR (measles, mumps, rubella) vaccination. For instance, in August 2024, the UK Health Security Agency reported a rise in measles cases, with the West Midlands region having the highest number of cases in 2023, contributing to a rise in mumps vaccinations as part of the broader infectious disease prevention efforts. Therefore, the rise in infectious diseases drives the mumps vaccine (mumpsvax) market.
Rising healthcare expenditure is expected to propel the growth of the mumps vaccine (mumpsvax) market. Healthcare expenditure refers to the total amount spent on health care goods and services, including personal healthcare, preventive services, and public health initiatives aimed at improving health outcomes. Factors like an aging population, chronic diseases, advanced medical technology, and increasing demand for services contribute to the rise in healthcare spending. This increase directly impacts Mumpsvax by improving funding for vaccination programs, thereby boosting vaccine accessibility and leading to higher immunization rates. For instance, in May 2024, the UK Office for National Statistics reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, reinforcing funding for vaccinations and improving public health outcomes. Therefore, the rise in healthcare expenditure drives the mumps vaccine (mumpsvax) market.
The increasing number of clinical trials is expected to propel the growth of the mumps vaccine (mumpsvax) market. Clinical trials are essential in advancing the understanding and treatment of various health conditions, including infectious diseases like mumps. Mumpsvax serves as a reliable tool for evaluating vaccine efficacy, safety, and immune response, particularly in trials focused on pediatric immunization and viral infections. For instance, in May 2023, Xtalks reported that over 452,000 clinical trials were registered globally, a significant increase from previous years. This growing number of clinical trials contributes to the continued development and assessment of vaccines like Mumpsvax. Therefore, the increase in clinical trials drives the mumps vaccine (mumpsvax) market.
Major players operating in the mumps vaccine (mumpsvax) market are Merck & Co. Inc.; GlaxoSmithKline plc
North America was the largest region in the mumps vaccine (mumpsvax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mumps vaccine (mumpsvax) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the mumps vaccine (mumpsvax) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The mumps vaccine (mumpsvax) market consists of sales of mumps vaccines, including both standalone mumps vaccines and combination vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Mumps Vaccine (MumpsVax) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on mumps vaccine (mumpsvax) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for mumps vaccine (mumpsvax) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mumps vaccine (mumpsvax) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.